➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKesson
McKinsey
Mallinckrodt
AstraZeneca
Boehringer Ingelheim

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

Vorapaxar sulfate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic drug sources for vorapaxar sulfate and what is the scope of patent protection?

Vorapaxar sulfate is the generic ingredient in one branded drug marketed by Xspire Pharma and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vorapaxar sulfate has one hundred and sixty-three patent family members in thirty-seven countries.

One supplier is listed for this compound.

Summary for vorapaxar sulfate
International Patents:163
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 35
Clinical Trials: 1
DailyMed Link:vorapaxar sulfate at DailyMed
Recent Clinical Trials for vorapaxar sulfate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme Corp.Phase 2
Matthew MellPhase 2

See all vorapaxar sulfate clinical trials

Pharmacology for vorapaxar sulfate

US Patents and Regulatory Information for vorapaxar sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xspire Pharma ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Xspire Pharma ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Xspire Pharma ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for vorapaxar sulfate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1495018 S1500036 Hungary ⤷  Free Forever Trial PRODUCT NAME: VORAPAXAR; REGISTRATION NO/DATE: EU/1/14/976 20150119
1495018 15C0047 France ⤷  Free Forever Trial PRODUCT NAME: VORAPAXAR,OU L'UN DE SES SELS OU SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150121
1495018 2015C/037 Belgium ⤷  Free Forever Trial PRODUCT NAME: VORAPAXAR, OU SON SEL OU SOLVAT PHARMACOLOGIQUEMENT ADMISSIBLE; AUTHORISATION NUMBER AND DATE: EU/1/14/976/001
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
McKinsey
Mallinckrodt
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.